GlassScriptPhysician profile
Gil U Kim
NPI 1821141482
$4,490.00
in general payments reported to CMS, 2019-2025
26 companies · $65.51 in 2025
The $65.51 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $1,060 · 2021: $321 · 2022: $522 · 2023: $641 · 2024: $449 · 2025: $65.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.54 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $779.88 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $698.12 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Lilly USA, LLC | $599.20 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $564.51 | 2019-2024 | |
| Abbvie INC. | $353.43 | 2019-2024 | |
| Astellas Pharma US INC | $287.33 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $240.50 | 2019-2024 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.01 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.45 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $94.76 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $82.45 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $60.00 | 2019 | |
| Esperion Therapeutics, INC. | $59.42 | 2021-2023 | Nexletol |
| Exact Sciences Corporation | $58.64 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $57.00 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $54.10 | 2019 | |
| Endo Pharmaceuticals INC. | $45.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.08 | 2019 | |
| Sumitomo Pharma America, INC. | $21.49 | 2023 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $20.35 | 2021 | |
| Janssen Biotech, INC. | $18.99 | 2019 | |
| Tactile Systems Technology INC | $17.47 | 2023 | Entre Plus, Flexitouch Plus |
| Allergan, INC. | $14.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.32 | 2019 | |
| Zyla Life Sciences, INC. | $13.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gil Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.